Breaking drug resistance in cancer through the development of a new class of therapies that target key drivers of ongoing DNA mutation and tumor evolution.
Location: United States, Washington, Seattle
Employees: 11-50
Total raised: $11M
Founded date: 2014
Investors 2
| Date | Name | Website |
| 08.12.2021 | M Ventures | m-ventures... |
| 17.07.2021 | ARCH Ventu... | archventur... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 23.08.2018 | Series A | $4M | - |
| 12.12.2016 | Series A | $7M | - |
Mentions in press and media 12
| Date | Title | Description |
| 24.08.2018 | Term Sheet — Friday, August 24 | THE BIG EVENT Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop The company said in a separate statement that the “number of shares to be offered and the price range for the offering hav... |
| 23.08.2018 | Accelerator’s ApoGen nets new biochem leaders, plus an additional $4M to target cancer resistance W h i t e p a p e r Vital Precision for Cost Reduction, QA, and Regulatory Compliance | ApoGen Biotechnologies has brought on Chrysalis Therapeutics founder Stephen Gwaltney, Ph.D., to be its VP of chemistry, and the Fred Hutchinson Cancer Research Center’s Peter de Vries, Ph.D., as senior director of biology. Sponsored by Agi... |
| 23.08.2018 | Accelerator’s ApoGen nets new biochem leaders, plus an additional $4M to target cancer resistance | ApoGen Biotechnologies has brought on Chrysalis Therapeutics founder Stephen Gwaltney, Ph.D., to be its VP of chemistry, and the Fred Hutchinson Cancer Research Center’s Peter de Vries, Ph.D., as senior director of biology. The Accelerator ... |
| 23.08.2018 | ApoGen raises additional $4M, adds three biotech vets in pursuit of better cancer treatment | (Bigstock Photo) Biotech startup ApoGen, which is researching solutions to drug-resistant cancers, is moving into a new phase of development. The company announced Thursday that it has raised an additional $4 million as part of its series A... |
| 23.08.2018 | ApoGen Biotechnologies Raises $4m in Series A Funding | ApoGen Biotechnologies, Inc., a Seattle, WA-based biotechnology company focused on the development of a new class of therapeutics targeting drivers of cancer genomic mutations, raised an additional $4m in Series A financing. M Ventures, the... |
| 23.08.2018 | ApoGen increases 2016 Series A funding round to $11 million | Accelerator CEO Thong Le is also CEO of ApoGen. Accelerator, which has offices in Seattle, San Diego and New York, has thus far provided $130 million to 19 companies, according to the firm’s website. Earlier this month, it launched Magnolia... |
| 13.12.2016 | ApoGen Biotechnologies Raises $7M in Series A Funding | ApoGen Biotechnologies, Inc., a Seattle, WA-based biotechnology company focused on the development of a new class of therapeutics targeting drivers of cancer genomic mutation, raised $7m in Series A financing. Backers included Accelerator C... |
| 12.12.2016 | Term Sheet — Monday, December 12 | TWINKIE RETURN, LAYOFF WATCH, AND THE NEW AUSTERITY The New York Times published a big feature on private equity over the weekend. It takes a slightly lighter touch than certain past magazine covers… A few takeaways: Paid Content How can yo... |
| 12.12.2016 | ApoGen secures $7M Series A with Accelerator Corporation | On Monday, the firm announced its third and final investment of the year, ApoGen Biotechnologies, with $7 million in new funding to begin its development journey with Accelerator. “We’re not quite an incubator, we’re not quite a venture cap... |
| 12.12.2016 | ApoGen Biotechnologies Grabs $7M in Series A | SEATTLE, WA, ApoGen Biotechnologies has raised a $7 million Series A financing. >> Click here for more funding data on ApoGen Biotechnologies >> To export ApoGen Biotechnologies funding data to PDF and Excel, click here A... |
Show more